Free Trial

Evotec (OTCMKTS:EVTCY) Stock Price Crosses Above 50-Day Moving Average - What's Next?

Evotec logo with Medical background
Remove Ads

Evotec SE (OTCMKTS:EVTCY - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.40 and traded as high as $4.47. Evotec shares last traded at $4.39, with a volume of 57,649 shares changing hands.

Evotec Trading Down 6.9 %

The stock has a market cap of $1.29 billion, a PE ratio of 9.56 and a beta of 0.98. The firm has a 50-day moving average price of $4.39 and a 200-day moving average price of $4.23. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.50 and a current ratio of 2.57.

Evotec Company Profile

(Get Free Report)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.

Further Reading

Should You Invest $1,000 in Evotec Right Now?

Before you consider Evotec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.

While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

HIMS Stock Up 120%! More Growth Ahead?

HIMS Stock Up 120%! More Growth Ahead?

Hims & Hers (NYSE: HIMS) has skyrocketed 120% in just a month! Is it the next big disruptor in healthcare, or is it overpriced?

Recent Videos

 5 Stocks to BUY NOW in April 2025
3 Bank Stocks Defying Market Turmoil—Cheap Options Trades!
Time to Buy SoFi? Fintech’s Next Big Move

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads